Long-term efficacy analysis of anti-IgE monoclonal antibody in patients with allergic asthma with chronic sinusitis with nasal polyps
Objective To observe the long-term efficacy of anti-IgE monoclonal antibody(omalizumab)in the treatment of allergic asthma combined with chronic sinusitis with nasal polyps(CRSwNP).Methods Clinical data of 4 patients with allergic asthma with CRSwNP between September 2020 and December 2023 were collected on visual analogue scale(VAS),sino-nasal outcome test-22(SNOT-22)scores and athma control test(ACT)scores baseline and at medication weeks 4,12,24 and 48.Observe the dynamic changes from baseline in VAS,SNOT-22 and ACT scores,and initially observe the long-term efficacy of omalizumab in allergic asthma with CRSwNP.Results After 48 weeks of omadizumab treatment,four patients showed improvement in nasal symptoms,effective control of allergic asthma symptoms,and improved quality of life.No serious adverse effects were observed during the treatment period.Conclusions This clinical observation preliminarily shows the long-term effectiveness of omalizumab in the treatment of allergic asthma combined with CRSwNP,but its efficacy and safety still need to be further confirmed by high-quality multicenter study with large clinical samples.
NETL
NSTL
万方数据
